查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1933380

子宫内膜异位症治疗市场规模、占有率、成长及全球产业分析：依类型、应用、区域洞察及预测（2026-2034 年）

Endometriosis Treatment Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 167 Pages | 商品交期: 请询问到货日

价格

子宫内膜异位症治疗市场成长驱动因子

全球子宫内膜异位症治疗市场持续稳定成长，主要受疾病认知度提高、诊断率上升以及育龄女性对先进治疗方案需求成长的推动。子宫内膜异位症是一种慢性妇科疾病，会促使骨盆腔疼痛、不孕症和生活品质下降，因此需要长期有效的治疗方法。根据 Fortune Business Insights 预测，全球子宫内膜异位症治疗市场规模预计将在 2025 年达到 23.9 亿美元，这反映了该治疗领域日益增长的临床和商业重要性。

市场规模及预测

预计到2026年，市场规模将成长至25.8亿美元，主要得益于诊断基础设施的改善、专科护理的普及以及创新药物疗法的推出。在预测期内，市场预计将显着扩张，到2034年达到50.3亿美元，复合年增长率（CAGR）为8.70%。

预计到2025年，北美将主导全球市场，占49.60%的市场占有率，这主要归功于该地区较高的疾病认知度、完善的医保报销体係以及众多大型製药公司的存在。

市场驱动因素

子宫内膜异位症治疗市场的主要驱动因素是对创新和疾病改善型治疗方案日益增长的需求。 传统疗法严重依赖荷尔蒙抑制，这通常会促使骨密度下降、情绪波动和不孕症等副作用。这些限制促使人们迫切需要更安全、非荷尔蒙标靶疗法，以解决发炎、免疫功能障碍和病灶生长等问题。

製药公司正积极投资研发，以满足这些未被满足的需求。例如，2025年1月，Celmatix Therapeutics启动了一项针对子宫内膜异位症疼痛和发炎的新型JNK抑制剂的开发项目，凸显了该行业向创新转型的趋势。

市场限制因子

儘管市场呈现成长趋势，但高昂的治疗费用仍是一个主要限制因素。口服GnRH拮抗剂等先进疗法的价格远高于一般荷尔蒙疗法，这限制了保险覆盖不足的患者获得治疗的机会。高额的自付费用往往会促使患者依从性差，最终促使治疗中断。

例如，据报道，Orilissa 的标价为每剂 1,046.66 美元，凸显了患者和医疗保健系统面临的经济负担。

市场机会

研发投入的增加为市场带来了丰厚的成长机会。由于目前一线疗法的疗效有限，药厂正致力于开发安全性更高、疗效更持久的新型疗法。

2025 年 1 月，Gesynta Pharma AB 获得了 2,870 万美元的 B 轮融资，用于推进其子宫内膜异位症候选药物 vipoglanstat 的 II 期临床试验。这些投资有望加速其产品线的开发和未来的市场扩张。

市场趋势

值得关注的市场趋势包括扩大宣传活动和病患权益倡议工作。 这些努力有助于促进早期诊断，减少对经痛的歧视，并教育病人和医护人员。

例如，2025年3月，国际妇产科超音波学会（ISUOG）举办了“2025年子宫内膜异位症宣传月”，旨在提高全球诊断率并促进治疗普及。

市场挑战

专利侵权和法律纠纷对市场成长构成重大挑战。专利相关的诉讼会缩短创新药的独占期，使仿製药能提前进入市场，进而侵蚀收入。

2025年5月，艾伯维公司（AbbVie Inc.）就其产品Orilissa对Hetero Labs Ltd.提起专利侵权诉讼，凸显了该领域创新公司面临的法律风险。

市场区隔分析

依药物类型划分， "其他" 细分市场占主导地位，这主要得益于传统且经济有效的治疗方法的广泛应用。 Orilissa 预计在 2026 年将占 11.18% 的市场占有率，而 Myfembree/Ryeqo 则有望因近期获准而实现较高的复合年增长率。

依药物类别划分，GnRH 拮抗剂在 2025 年占市场主导地位，预计在 2026 年将占 40.17% 的市场占有率。这主要归功于其起效迅速和安全性更高。

依给药途径划分，口服给药途径将在 2026 年占领先地位，市场占有率将达到 65.46%，这主要得益于患者依从性高和给药便利性。

依分销管道划分，药房和零售药房将引领市场，到 2026 年将占 59.20% 的市场占有率。

区域展望

北美预计将引领市场，在 2025 年达到 11.9 亿美元，2026 年达到 12.8 亿美元，这主要得益于其完善的医疗保健基础设施和疾病盛行率的上升。

预计到 2025 年，欧洲市场规模将达到 5.6 亿美元，而亚太地区，在中印两国日益增长的认知度推动下，预计到 2025 年将达到 4.6 亿美元。

预计拉丁美洲和中东及非洲市场将呈现温和成长，到 2025 年，市场规模分别为 9,000 万美元和 5,000 万美元。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇
  • 市场趋势

第四章：关键资讯洞察

  • 主要国家的监管环境
  • 主要公司产品线分析
  • 主要国家的子宫内膜异位症流行病学
  • 主要产业趋势（併购、合作、新产品发表等）

第五章：全球子宫内膜异位症治疗市场分析、洞察与预测（2021-2034）

  • 依治疗药物划分的市场分析、洞察与预测
    • Orilissa
    • Myfembree/Lyco
    • 其他
  • 依治疗类别划分的市场分析、洞察与预测
    • GnRH拮抗剂
    • GnRH激动剂
    • 其他
  • 市场分析、洞察与预测 - 依给药途径
    • 口服
    • 其他
  • 市场分析、洞察与预测 - 依销售管道
    • 医院药房
    • 零售药房
    • 线上药房
  • 市场分析、洞察与预测 - 依地区
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章 北美子宫内膜异位症治疗市场分析、洞察与预测，2021-2034

  • 依国家/地区
    • 美国各州
    • 加拿大

第七章：欧洲子宫内膜异位症治疗市场分析、洞察与预测（2021-2034）

  • 依国家划分
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 斯堪的纳维亚半岛
    • 欧洲其他地区

第八章：亚太地区子宫内膜异位症治疗市场分析、洞察与预测（2021-2034）

  • 依国家划分
    • 中国
    • 日本
    • 印度
    • 东南亚
    • 澳大利亚
    • 亚太其他地区

第九章：拉丁美洲子宫内膜异位症治疗市场分析、洞察与预测（2021-2034）

  • 依国家划分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区

第十章 中东与非洲子宫内膜异位症治疗市场分析、洞察与预测（2021-2034）

  • 依国家划分
    • 海湾合作委员会
    • 南非
    • 中东和非洲其他地区

第十一章 竞争分析

  • 全球市占率分析（2026）
  • 公司简介
  • Gesynta Pharma AB
  • Gesynta Pharma AB
  • AbbVie Inc.
  • Pfizer Inc.
  • Organon group of companies.
  • Bayer AG
  • AstraZeneca
  • Sumitomo Pharma Co., Ltd.
Product Code: FBI114330

Growth Factors of endometriosis treatment Market

The global endometriosis treatment market is witnessing steady expansion, driven by increasing disease awareness, rising diagnosis rates, and growing demand for advanced therapeutic solutions among women of reproductive age. Endometriosis is a chronic gynecological condition associated with pelvic pain, infertility, and reduced quality of life, creating a significant need for long-term and effective treatment options. According to Fortune Business Insights, the global endometriosis treatment market was valued at USD 2.39 billion in 2025, reflecting the growing clinical and commercial importance of this therapeutic area.

Market Size and Forecast

In 2026, the market is projected to grow to USD 2.58 billion, supported by improved diagnostic infrastructure, increasing access to specialty care, and the introduction of innovative drug therapies. Over the forecast period, the market is expected to expand significantly and reach USD 5.03 billion by 2034, registering a CAGR of 8.70%.

North America dominated the global market in 2025, accounting for a 49.60% market share, owing to high disease awareness, strong reimbursement frameworks, and the presence of leading pharmaceutical companies.

Market Drivers

A major driver of the endometriosis treatment market is the increasing demand for innovative and disease-modifying treatment alternatives. Traditional therapies rely heavily on hormonal suppression, which often results in adverse effects such as bone density loss, mood changes, and fertility concerns. These limitations have created strong demand for safer, non-hormonal, and targeted therapies that address inflammation, immune dysfunction, and lesion growth.

Pharmaceutical companies are actively investing in research and development to address these unmet needs. For example, in January 2025, Celmatix Therapeutics launched a drug development program for a novel JNK inhibitor targeting pain and inflammation in endometriosis, highlighting the industry's shift toward innovation.

Market Restraints

Despite positive growth trends, high treatment costs remain a key restraint. Advanced therapies such as oral GnRH antagonists are significantly more expensive than generic hormonal treatments, limiting accessibility for patients without adequate insurance coverage. High out-of-pocket costs often result in non-adherence or treatment discontinuation.

For instance, the list price of Orilissa was reported at USD 1,046.66 per dose, illustrating the affordability challenges faced by patients and healthcare systems.

Market Opportunities

Rising investments in research and development present lucrative growth opportunities for the market. With current first-line treatments offering limited relief, pharmaceutical companies are focusing on developing novel therapies with improved safety and long-term efficacy.

In January 2025, Gesynta Pharma AB secured USD 28.7 million in Series B funding to advance a Phase II clinical trial for Vipoglanstat, a promising drug candidate for endometriosis. Such investments are expected to accelerate product pipelines and support future market expansion.

Market Trends

A prominent trend in the market is the expansion of awareness campaigns and patient support initiatives. These efforts promote early diagnosis, reduce stigma around menstrual pain, and educate both patients and clinicians.

For example, in March 2025, the International Society of Ultrasound in Obstetrics and Gynecology (ISUOG) organized Endometriosis Awareness Month 2025, contributing to increased diagnosis rates and treatment adoption globally.

Market Challenges

Patent infringement and legal disputes pose a critical challenge to market growth. Patent-related litigation can reduce exclusivity periods for innovative drugs, enabling early entry of generics and causing revenue erosion.

In May 2025, AbbVie Inc. filed a patent infringement lawsuit against Hetero Labs Ltd. concerning Orilissa, highlighting the legal risks faced by innovators in this space.

Segmentation Analysis

By drug, the others segment dominates the market due to widespread use of older, cost-effective therapies. Orilissa held an 11.18% market share in 2026, while Myfembree/Ryeqo is expected to grow at a strong CAGR due to recent approvals.

By drug class, GnRH antagonists dominated in 2025 and accounted for 40.17% market share in 2026, driven by faster action and improved safety profiles.

By route of administration, the oral segment dominated with a 65.46% share in 2026, supported by high patient adherence and convenience.

By distribution channel, drug stores and retail pharmacies led the market, holding 59.20% share in 2026.

Regional Outlook

North America led the market with USD 1.19 billion in 2025 and USD 1.28 billion in 2026, driven by strong healthcare infrastructure and rising prevalence.

Europe recorded USD 0.56 billion in 2025, while Asia Pacific reached USD 0.46 billion in 2025, supported by growing awareness in China and India.

Latin America and Middle East & Africa showed moderate growth, with valuations of USD 0.09 billion and USD 0.05 billion respectively in 2025.

Competitive Landscape

The market is semi-consolidated, with key players including AbbVie Inc., Pfizer Inc., Bayer AG, AstraZeneca, and Organon. These companies maintain leadership through strong pipelines, global distribution networks, and continuous R&D investments.

Conclusion

The global endometriosis treatment market is poised for strong growth, expanding from USD 2.39 billion in 2025 to USD 5.03 billion by 2034, driven by rising disease awareness, improved diagnostics, and increasing demand for innovative therapies. While high treatment costs and patent-related challenges may limit adoption, growing R&D investments, non-hormonal drug development, and expanding awareness initiatives are expected to create sustainable growth opportunities. Overall, the market is set to evolve significantly, offering improved treatment outcomes and long-term management solutions for women affected by endometriosis worldwide.

Segmentation By Drug, Drug Class, Route of Administration, Distribution Channel, and Region

By Drug * Orilissa

  • Myfembree/Ryeqo
  • Others

By Drug Class * GnRH Antagonists

  • GnRH Agonists
  • Others

By Route of Administration * Oral

  • Others

By Distribution Channel * Hospital Pharmacies

  • Retail Pharmacies
  • Online Pharmacies

By Geography * North America (By Drug, Drug Class, Route of Administration, Distribution Channel, and Country)

    • U.S.
    • Canada
  • Europe (By Drug, Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Drug, Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Drug, Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Drug, Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Regulatory Scenarios, By Key Countries/Regions
  • 4.2. Pipeline Analysis, By Key Players
  • 4.3. Epidemiology- Endometriosis, By Key Countries/ Regions
  • 4.4. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)

5. Global Endometriosis Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Drug
    • 5.1.1. Orilissa
    • 5.1.2. Myfembree/Ryeqo
    • 5.1.3. Others
  • 5.2. Market Analysis, Insights and Forecast - By Drug Class
    • 5.2.1. GnRH Antagonists
    • 5.2.2. GnRH Agonists
    • 5.2.3. Others
  • 5.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.3.1. Oral
    • 5.3.2. Others
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospital Pharmacies
    • 5.4.2. Retail Pharmacies
    • 5.4.3. Online Pharmacies
  • 5.5. Market Analysis, Insights and Forecast - Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Endometriosis Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Drug
    • 6.1.1. Orilissa
    • 6.1.2. Myfembree/Ryeqo
    • 6.1.3. Others
  • 6.2. Market Analysis, Insights and Forecast - By Drug Class
    • 6.2.1. GnRH Antagonists
    • 6.2.2. GnRH Agonists
    • 6.2.3. Others
  • 6.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.3.1. Oral
    • 6.3.2. Others
  • 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.4.1. Hospital Pharmacies
    • 6.4.2. Retail Pharmacies
    • 6.4.3. Online Pharmacies
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Endometriosis Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Drug
    • 7.1.1. ORILISSA
    • 7.1.2. MYFEMBREE/RYEQO
    • 7.1.3. Others
  • 7.2. Market Analysis, Insights and Forecast - By Drug Class
    • 7.2.1. GnRH Antagonists
    • 7.2.2. GnRH Agonists
    • 7.2.3. Others
  • 7.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.3.1. Oral
    • 7.3.2. Others
  • 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.4.1. Hospital Pharmacies
    • 7.4.2. Retail Pharmacies
    • 7.4.3. Online Pharmacies
  • 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.5.1. U.K.
    • 7.5.2. Germany
    • 7.5.3. France
    • 7.5.4. Italy
    • 7.5.5. Spain
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Endometriosis Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Drug
    • 8.1.1. Orilissa
    • 8.1.2. Myfembree/Ryeqo
    • 8.1.3. Others
  • 8.2. Market Analysis, Insights and Forecast - By Drug Class
    • 8.2.1. GnRH Antagonists
    • 8.2.2. GnRH Agonists
    • 8.2.3. Others
  • 8.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.3.1. Oral
    • 8.3.2. Others
  • 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.4.1. Hospital Pharmacies
    • 8.4.2. Retail Pharmacies
    • 8.4.3. Online Pharmacies
  • 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.5.1. China
    • 8.5.2. Japan
    • 8.5.3. India
    • 8.5.4. Southeast Asia
    • 8.5.5. Australia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Endometriosis Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Drug
    • 9.1.1. Orilissa
    • 9.1.2. Myfembree/Ryeqo
    • 9.1.3. Others
  • 9.2. Market Analysis, Insights and Forecast - By Drug Class
    • 9.2.1. GnRH Antagonists
    • 9.2.2. GnRH Agonists
    • 9.2.3. Others
  • 9.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.3.1. Oral
    • 9.3.2. Others
  • 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.4.1. Hospital Pharmacies
    • 9.4.2. Retail Pharmacies
    • 9.4.3. Online Pharmacies
  • 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Endometriosis Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Drug
    • 10.1.1. Orilissa
    • 10.1.2. Myfembree/Ryeqo
    • 10.1.3. Others
  • 10.2. Market Analysis, Insights and Forecast - By Drug Class
    • 10.2.1. GnRH Antagonists
    • 10.2.2. GnRH Agonists
    • 10.2.3. Others
  • 10.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.3.1. Oral
    • 10.3.2. Others
  • 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Retail Pharmacies
    • 10.4.3. Online Pharmacies
  • 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.5.1. GCC
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2026)
  • 11.2. Company Profiles (Overview, Products, SWOT Analysis, Recent Developments, Strategies, Financials (Based on Availability))
    • 11.2.1. Gesynta Pharma AB
    • 11.2.2. AbbVie Inc.
    • 11.2.3. Pfizer Inc.
    • 11.2.4. Organon group of companies.
    • 11.2.5. Bayer AG
    • 11.2.6. AstraZeneca
    • 11.2.7. Sumitomo Pharma Co., Ltd.

List of Tables

  • Table 1: Global Endometriosis Treatment Market Revenue (USD billion) Forecast, By Drug, 2021-2034
  • Table 2: Global Endometriosis Treatment Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 3: Global Endometriosis Treatment Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 4: Global Endometriosis Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 5: Global Endometriosis Treatment Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 6: North America Endometriosis Treatment Market Revenue (USD billion) Forecast, By Drug, 2021-2034
  • Table 7: North America Endometriosis Treatment Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 8: North America Endometriosis Treatment Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 9: North America Endometriosis Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 10: North America Endometriosis Treatment Market Revenue (USD billion) Forecast, by Country, 2021-2034
  • Table 11: Europe Endometriosis Treatment Market Revenue (USD billion) Forecast, By Drug, 2021-2034
  • Table 12: Europe Endometriosis Treatment Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 13: Europe Endometriosis Treatment Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 14: Europe Endometriosis Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 15: Europe Endometriosis Treatment Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
  • Table 16: Asia Pacific Endometriosis Treatment Market Revenue (USD billion) Forecast, By Drug, 2021-2034
  • Table 17: Asia Pacific Endometriosis Treatment Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 18: Asia Pacific Endometriosis Treatment Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 19: Asia Pacific Endometriosis Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 20: Asia Pacific Endometriosis Treatment Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
  • Table 21: Latin America Endometriosis Treatment Market Revenue (USD billion) Forecast, By Drug, 2021-2034
  • Table 22: Latin America Endometriosis Treatment Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 23: Latin America Endometriosis Treatment Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 24: Latin America Endometriosis Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 25: Latin America Endometriosis Treatment Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
  • Table 26: Middle East & Africa Endometriosis Treatment Market Revenue (USD billion) Forecast, By Drug, 2021-2034
  • Table 27: Middle East & Africa Endometriosis Treatment Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 28: Middle East & Africa Endometriosis Treatment Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 29: Middle East & Africa Endometriosis Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 30: Middle East & Africa Endometriosis Treatment Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Endometriosis Treatment Market Revenue Breakdown (USD billion, %) by Region, 2026 & 2034
  • Figure 2: Global Endometriosis Treatment Market Value Share (%), By Drug, 2026 & 2034
  • Figure 3: Global Endometriosis Treatment Market Value Share (%), by Drug Class, 2026 & 2034
  • Figure 4: Global Endometriosis Treatment Market Value Share (%), by Route of Administration, 2026 & 2034
  • Figure 5: Global Endometriosis Treatment Market Value Share (%), by Distribution Channel, 2026 & 2034
  • Figure 6: Global Endometriosis Treatment Market Value Share (%), by Region, 2026 & 2034
  • Figure 7: North America Endometriosis Treatment Market Value (USD billion), By Drug, 2026 & 2034
  • Figure 8: North America Endometriosis Treatment Market Value Share (%), By Drug, 2026
  • Figure 9: North America Endometriosis Treatment Market Value (USD billion), by Drug Class, 2026 & 2034
  • Figure 10: North America Endometriosis Treatment Market Value Share (%), by Drug Class, 2026
  • Figure 11: North America Endometriosis Treatment Market Value (USD billion), by Route of Administration, 2026 & 2034
  • Figure 12: North America Endometriosis Treatment Market Value Share (%), by Route of Administration, 2026
  • Figure 13: North America Endometriosis Treatment Market Value (USD billion), by Distribution Channel, 2026 & 2034
  • Figure 14: North America Endometriosis Treatment Market Value Share (%), by Distribution Channel, 2026
  • Figure 15: North America Endometriosis Treatment Market Value (USD billion), by Country, 2026 & 2034
  • Figure 16: North America Endometriosis Treatment Market Value Share (%), by Country, 2026
  • Figure 17: Europe Endometriosis Treatment Market Value (USD billion), By Drug, 2026 & 2034
  • Figure 18: Europe Endometriosis Treatment Market Value Share (%), By Drug, 2026
  • Figure 19: Europe Endometriosis Treatment Market Value (USD billion), by Drug Class, 2026 & 2034
  • Figure 20: Europe Endometriosis Treatment Market Value Share (%), by Drug Class, 2026
  • Figure 21: Europe Endometriosis Treatment Market Value (USD billion), by Route of Administration, 2026 & 2034
  • Figure 22: Europe Endometriosis Treatment Market Value Share (%), by Route of Administration, 2026
  • Figure 23: Europe Endometriosis Treatment Market Value (USD billion), by Distribution Channel, 2026 & 2034
  • Figure 24: Europe Endometriosis Treatment Market Value Share (%), by Distribution Channel, 2026
  • Figure 25: Europe Endometriosis Treatment Market Value (USD billion), by Country/ Sub-region, 2026 & 2034
  • Figure 26: Europe Endometriosis Treatment Market Value Share (%), by Country/ Sub-region, 2026
  • Figure 27: Asia Pacific Endometriosis Treatment Market Value (USD billion), By Drug, 2026 & 2034
  • Figure 28: Asia Pacific Endometriosis Treatment Market Value Share (%), By Drug, 2026
  • Figure 29: Asia Pacific Endometriosis Treatment Market Value (USD billion), by Drug Class, 2026 & 2034
  • Figure 30: Asia Pacific Endometriosis Treatment Market Value Share (%), by Drug Class, 2026
  • Figure 31: Asia Pacific Endometriosis Treatment Market Value (USD billion), by Route of Administration, 2026 & 2034
  • Figure 32: Asia Pacific Endometriosis Treatment Market Value Share (%), by Route of Administration, 2026
  • Figure 33: Asia Pacific Endometriosis Treatment Market Value (USD billion), by Distribution Channel, 2026 & 2034
  • Figure 34: Asia Pacific Endometriosis Treatment Market Value Share (%), by Distribution Channel, 2026
  • Figure 35: Asia Pacific Endometriosis Treatment Market Value (USD billion), by Country/ Sub-region, 2026 & 2034
  • Figure 36: Asia Pacific Endometriosis Treatment Market Value Share (%), by Country/ Sub-region, 2026
  • Figure 37: Latin America Endometriosis Treatment Market Value (USD billion), By Drug, 2026 & 2034
  • Figure 38: Latin America Endometriosis Treatment Market Value Share (%), By Drug, 2026
  • Figure 39: Latin America Endometriosis Treatment Market Value (USD billion), by Drug Class, 2026 & 2034
  • Figure 40: Latin America Endometriosis Treatment Market Value Share (%), by Drug Class, 2026
  • Figure 41: Latin America Endometriosis Treatment Market Value (USD billion), by Route of Administration, 2026 & 2034
  • Figure 42: Latin America Endometriosis Treatment Market Value Share (%), by Route of Administration, 2026
  • Figure 43: Latin America Endometriosis Treatment Market Value (USD billion), by Distribution Channel, 2026 & 2034
  • Figure 44: Latin America Endometriosis Treatment Market Value Share (%), by Distribution Channel, 2026
  • Figure 45: Latin America Endometriosis Treatment Market Value (USD billion), by Country/ Sub-region, 2026 & 2034
  • Figure 46: Latin America Endometriosis Treatment Market Value Share (%), by Country/ Sub-region, 2026
  • Figure 47: Middle East & Africa Endometriosis Treatment Market Value (USD billion), By Drug, 2026 & 2034
  • Figure 48: Middle East & Africa Endometriosis Treatment Market Value Share (%), By Drug, 2026
  • Figure 49: Middle East & Africa Endometriosis Treatment Market Value (USD billion), by Drug Class, 2026 & 2034
  • Figure 50: Middle East & Africa Endometriosis Treatment Market Value Share (%), by Drug Class, 2026
  • Figure 51: Middle East & Africa Endometriosis Treatment Market Value (USD billion), by Route of Administration, 2026 & 2034
  • Figure 52: Middle East & Africa Endometriosis Treatment Market Value Share (%), by Route of Administration, 2026
  • Figure 53: Middle East & Africa Endometriosis Treatment Market Value (USD billion), by Distribution Channel, 2026 & 2034
  • Figure 54: Middle East & Africa Endometriosis Treatment Market Value Share (%), by Distribution Channel, 2026
  • Figure 55: Middle East & Africa Endometriosis Treatment Market Value (USD billion), by Country/ Sub-region, 2026 & 2034
  • Figure 56: Middle East & Africa Endometriosis Treatment Market Value Share (%), by Country/ Sub-region, 2026
  • Figure 57: Global Endometriosis Treatment Market Share (%), by Company, 2026